Miami Cancer Institute - Multispecialty Grand Rounds Evaluation - January 12, 2026

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC).	Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC). - 5	Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC). - 4	Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC). - 3	Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC). - 2	Demonstrate the ability to identify appropriate candidates for neoadjuvant chemotherapy and immunotherapy followed by surgical resection in non-small cell lung cancer (NSCLC). - 1
Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC.	Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC. - 5	Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC. - 4	Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC. - 3	Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC. - 2	Accurately differentiate clinical trial designs, endpoints, and reported outcomes across neoadjuvant, peri-operative, and adjuvant immunotherapy studies in NSCLC. - 1
Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC.	Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC. - 5	Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC. - 4	Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC. - 3	Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC. - 2	Apply evidence-based criteria to recognize patients who are not suitable candidates for immunotherapy in early-stage NSCLC. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice

	5	4	3	2	1
Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC?	Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC? - 5	Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC? - 4	Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC? - 3	Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC? - 2	Identify patients who may be eligible for neoadjuvant chemotherapy and immunotherapy followed by surgery for NSCLC? - 1
Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC?	Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC? - 5	Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC? - 4	Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC? - 3	Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC? - 2	Recognize patients who would not be appropriate candidates for immunotherapy treatment in early stage NSCLC? - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so?

Please provide any additional comments or suggestions.

Name and ABS ID Required to claim MOC *

You are here

Miami Cancer Institute - Multispecialty Grand Rounds Evaluation - January 12, 2026